September 1, 2017 - Launch of the Next Generation T-Track® CMV Immune Monitoring Tool

Today Lophius Biosciences launched the next generation of its in vitro diagnostic test T-Track® CMV for the risk stratification of human cytomegalovirus (CMV)-related clinical complications in transplant recipients.

Read more

May 31, 2017 – Lophius Biosciences Receives Public Grant for the Development of an Advanced Diagnostic Tuberculosis Test

Lophius Biosciences GmbH today announced that it has been awarded a public grant funding of 0.65 MEUR from the German Federal Ministry of Education and Research to develop a blood based diagnostic test for the rapid and efficient diagnosis of tuberculosis.

Read more

April 05, 2017 - Clinical Validation of T-Track® CMV

Publication of two peer-reviewed scientific papers covering the company’s CE-marked in vitro diagnostic test T-Track® CMV.

Read more

March 22, 2017 - Lophius Biosciences Appoints Robert J. Silverman as Supervisory Board Member

Lophius Biosciences today announced the appointment of former CEO of mtm Laboratories AG Robert J. Silverman to the Company’s Supervisory Board

Read more

March 16, 2017 – Lophius Biosciences Completes Extension of its Financing Round to €7.36 Million

Lophius Biosciences GmbH today announced the extension of the first tranche of the recently closed financing round by €5.2m to €7.4m.

Read more

July 26, 2016 – Lophius Biosciences Closed Financing Round of €4.25 Million to Expand Diagnostic Developments into Tuberculosis and to Strengthen Marketing Activities

Lophius today announced the completion of a €4.25m financing round, led by VRD GmbH, supported by Bayern Kapital GmbH and two private investors with Wolf Biotech GmbH and WIC GmbH.

Read more
This function requires IE9 or higher.
You can update your browser under:
http://windows.microsoft.com/de-DE/internet-explorer/download-ie